Maier Paul V's Form 4 filing
Eton Pharmaceuticals, Inc. (ETON) · filed Aug 28, 2026
- Accession no.
- 0001437749-26-029196
- Filed
- Aug 28, 2026, 4:51 PM ET
- Trade date
- Aug 28, 2026
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions and 1 derivative transaction. Open-market sales total $2.95M. It was filed on the trade date.
This filing was later replaced by the amendment 0001437749-26-029308 (Aug 31, 2026). Trade tables on this site use the amended version.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Maier Paul VCIK 0001182615 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 28, 2026 | Common Stock | MOption exerciseAcquired | +50,000 | $3.78 | +$189,000 | 109,745 | Direct | |
| Aug 28, 2026 | Common Stock | SSaleDisposed | −36,387 | $58.64F1,F2 | −$2,133,733.68 | 73,358 | Direct | |
| Aug 28, 2026 | Common Stock | SSaleDisposed | −13,485 | $60.21F1,F4 | −$811,931.85 | 59,873 | Direct | |
| Aug 28, 2026 | Common Stock | SSaleDisposed | −128 | $61.77F1,F5 | −$7,906.56 | 59,745 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 28, 2026 | Common Stock | MOption exerciseDisposed | −50,000 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.
Referenced by the price of 3 transactions in Table I.
- F2
The shares were sold in multiple trades at prices ranging from $58.50 to $58.97. The price reported above reflects the weighted average sales price.
Referenced by the price of 1 transaction in Table I.
- F4
The shares were sold in multiple trades at prices ranging from $60.00 to $61.00. The price reported above reflects the weighted average sales price.
Referenced by the price of 1 transaction in Table I.
- F5
The shares were sold in multiple trades at prices ranging from $61.10 to $61.98. The price reported above reflects the weighted average sales price.
Referenced by the price of 1 transaction in Table I.
Remarks
The reporting person has authorized and designated the named person to file this Form 4 on the reporting person's behalf for indefinite duration.